Xospata (gilteritinib) is a small molecule pharmaceutical. Gilteritinib was first approved as Xospata on 2018-11-28. It is used to treat myeloid leukemia acute in the USA. It has been approved in Europe to treat myeloid leukemia acute. It is known to target tyrosine-protein kinase receptor UFO, high affinity nerve growth factor receptor, proto-oncogene tyrosine-protein kinase receptor Ret, tyrosine-protein kinase Mer, leukocyte tyrosine kinase receptor, proto-oncogene tyrosine-protein kinase ROS, receptor-type tyrosine-protein kinase FLT3, ALK tyrosine kinase receptor, and fms-related tyrosine kinase 3 ligand. Xospata's patents are valid until 2036-07-01 (FDA).
|Indication||myeloid leukemia acute|
|Drug Class||Tyrosine kinase inhibitors|